FULC vs. CDMO, ANNX, MRSN, LRMR, NGNE, TVTX, TBPH, HRTX, HROW, and OCS
Should you be buying Fulcrum Therapeutics stock or one of its competitors? The main competitors of Fulcrum Therapeutics include Avid Bioservices (CDMO), Annexon (ANNX), Mersana Therapeutics (MRSN), Larimar Therapeutics (LRMR), Neurogene (NGNE), Travere Therapeutics (TVTX), Theravance Biopharma (TBPH), Heron Therapeutics (HRTX), Harrow Health (HROW), and Oculis (OCS). These companies are all part of the "pharmaceutical preparations" industry.
Fulcrum Therapeutics (NASDAQ:FULC) and Avid Bioservices (NASDAQ:CDMO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, community ranking, analyst recommendations, institutional ownership, media sentiment, profitability and earnings.
Avid Bioservices has a net margin of -8.12% compared to Fulcrum Therapeutics' net margin of -3,470.05%. Avid Bioservices' return on equity of -5.18% beat Fulcrum Therapeutics' return on equity.
Avid Bioservices received 274 more outperform votes than Fulcrum Therapeutics when rated by MarketBeat users. Likewise, 66.42% of users gave Avid Bioservices an outperform vote while only 63.89% of users gave Fulcrum Therapeutics an outperform vote.
Fulcrum Therapeutics has a beta of 2.29, suggesting that its share price is 129% more volatile than the S&P 500. Comparatively, Avid Bioservices has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500.
Fulcrum Therapeutics currently has a consensus price target of $13.17, suggesting a potential upside of 81.61%. Avid Bioservices has a consensus price target of $14.25, suggesting a potential upside of 122.31%. Given Avid Bioservices' higher probable upside, analysts clearly believe Avid Bioservices is more favorable than Fulcrum Therapeutics.
Avid Bioservices has higher revenue and earnings than Fulcrum Therapeutics. Avid Bioservices is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Avid Bioservices had 3 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 5 mentions for Avid Bioservices and 2 mentions for Fulcrum Therapeutics. Avid Bioservices' average media sentiment score of 1.16 beat Fulcrum Therapeutics' score of 0.71 indicating that Avid Bioservices is being referred to more favorably in the news media.
89.8% of Fulcrum Therapeutics shares are held by institutional investors. Comparatively, 97.2% of Avid Bioservices shares are held by institutional investors. 2.5% of Fulcrum Therapeutics shares are held by insiders. Comparatively, 2.4% of Avid Bioservices shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Avid Bioservices beats Fulcrum Therapeutics on 12 of the 18 factors compared between the two stocks.
Get Fulcrum Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FULC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FULC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fulcrum Therapeutics Competitors List
Related Companies and Tools
